The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
Open accessAbstract
// Masanori Hasegawa 1 , Hidekazu Takahashi 1,3 , Hasan Rajabi 1 , Maroof Alam 1 , Yozo Suzuki 1,4 , Li Yin 1 , Ashujit Tagde 1 , Takahiro Maeda 1 , Masayuki Hiraki 1 , Vikas P. Sukhatme 2 and Donald Kufe 1 1 Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 2 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA 3 Department of Gastrointestinal Surgery, Graduate School of Medicine, Osaka University, Suita City, Osaka, Japan 4 Department of Gastroenterological Surgery, Osaka Police Hospital, Osaka City, Osaka, Japan Correspondence to: Donald Kufe, email: // Keywords : xCT, MUC1-C, CD44v, epigenetics, ferroptosis Received : December 11, 2015 Accepted : January 26, 2016 Published : February 22, 2016 Abstract The xCT light chain of the cystine/glutamate transporter (system X C - ) is of importance for the survival of triple-negative breast cancer (TNBC) cells. The MUC1-C transmembrane oncoprotein is aberrantly overexpressed in TNBC and, like xCT, has been linked to maintaining glutathione (GSH) levels and redox balance. However, there is no known interaction between MUC1-C and xCT. Here we show that silencing MUC1-C is associated with decreases in xCT expression in TNBC cells. The results demonstrate that MUC1-C forms a complex with xCT and the CD44 variant (CD44v), which interacts with xCT and thereby controls GSH levels. MUC1-C binds directly with CD44v and in turn promotes stability of xCT in the cell membrane. The interaction between MUC1-C and xCT is further supported by the demonstration that targeting xCT with silencing or the inhibitor sulfasalazine suppresses MUC1 gene transcription by increasing histone and DNA methylation on the MUC1 promoter. In terms of the functional significance of the MUC1-C/xCT interaction, we show that MUC1-C protects against treatment with erastin, an inhibitor of X C - and inducer of ferroptosis, a form of non-apoptotic cell death. These findings indicate that targeting this novel MUC1-C/xCT pathway could represent a potential therapeutic approach for promoting TNBC cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intrinsically unstructured proteins and their functions
Dyson, H. J., & Wright, P. E. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1589 · Cited by 3,871
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262
Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192
Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 5×
“Inhibition of xCT in TNBC cells with the clinically approved anti-inflammatory agent sulfasalazine (SASP) decreases cystine uptake, GSH production and tumor growth [8].”
InfluentialRedox imbalance in cystine/glutamate transporter-deficient mice
Sato, H., Shiiya, A., Kimata, M., Maebara, K., Tamba, M., Sakakura, Y., Makino, N., Sugiyama, F., Yagami, K.-I., Moriguchi, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506439200 · Cited by 422
The x cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases
Lo, M., Wang, Y., & Gout, P. W. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21366 · Cited by 399
Cited by
Ferroptosis: molecular mechanisms and health implications
Tang, D., Chen, X., Kang, R., & Kroemer, G. (2021) · Cell Research · doi:10.1038/s41422-020-00441-1 · Cited by 4,256
Ferroptosis: past, present and future
Li, J., Cao, F., Yin, H.-L., Huang, Z.-J., Lin, Z.-T., Mao, N., Sun, B., & Wang, G. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2298-2 · Cited by 4,171
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0720-y · Cited by 1,930
ATF3 promotes erastin-induced ferroptosis by suppressing system Xc–
Wang, L., Liu, Y., Du, T., Yang, H., Lei, L., Guo, M., Ding, H.-F., Zhang, J., Wang, H., Chen, X., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-019-0380-z · Cited by 809
Ferroptosis, a new form of cell death, and its relationships with tumourous diseases
Yu, H., Guo, P., Xie, X., Wang, Y., & Chen, G. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13008 · Cited by 710
Ferroptosis in cancer and cancer immunotherapy
Zhao, L., Zhou, X., Xie, F., Zhang, L., Yan, H., Huang, J., Zhang, C., Zhou, F., Chen, J., & Zhang, L. (2022) · Cancer Communications · doi:10.1002/cac2.12250 · Cited by 684
The multifaceted role of ferroptosis in liver disease
Chen, J., Li, X., Ge, C., Min, J., & Wang, F. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00941-0 · Cited by 665
Oxidative Damage and Antioxidant Defense in Ferroptosis
Kuang, F., Liu, J., Tang, D., & Kang, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.586578 · Cited by 531
The Role of Ferroptosis in Cancer Development and Treatment Response
Lu, B., Chen, X. B., Ying, M. D., He, Q. J., Cao, J., & Yang, B. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00992 · Cited by 444
Li, F.-J., Long, H.-Z., Zhou, Z.-W., Luo, H.-Y., Xu, S.-G., & Gao, L.-C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.910292 · Cited by 438
Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis
Tian, R., Abarientos, A., Hong, J., Hashemi, S. H., Yan, R., Dräger, N., Leng, K., Nalls, M. A., Singleton, A. B., Xu, K., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00862-0 · Cited by 414
Ferroptosis Mechanisms Involved in Neurodegenerative Diseases
Reichert, C. O., de Freitas, F. A., Sampaio-Silva, J., Rokita-Rosa, L., Barros, P. D. L., Levy, D., & Bydlowski, S. P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228765 · Cited by 422
Ding, Y., Chen, X., Liu, C., Ge, W., Wang, Q., Hao, X., Wang, M., Chen, Y., & Zhang, Q. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01016-8 · Cited by 415
Genome-wide CRISPRi/a screens in human neurons link lysosomal failure to ferroptosis
Tian, R., Abarientos, A., Hong, J., Hashemi, S. H., Yan, R., Dräger, N., Leng, K., Nalls, M. A., Singleton, A. B., Xu, K., et al. (2020) · doi:10.1101/2020.06.27.175679 · Cited by 414
Deshmukh, P., Unni, S., Krishnappa, G., & Padmanabhan, B. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0244-4 · Cited by 398
Overcoming cancer chemotherapy resistance by the induction of ferroptosis
Wang, Y., Wu, X., Ren, Z., Li, Y., Zou, W., Chen, J., & Wang, H. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100916 · Cited by 361
Emerging mechanisms and targeted therapy of ferroptosis in cancer
Wang, H., Cheng, Y., Mao, C., Liu, S., Xiao, D., Huang, J., & Tao, Y. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.03.022 · Cited by 312
Chen, M.-S., Wang, S.-F., Hsu, C.-Y., Yin, P.-H., Yeh, T.-S., Lee, H.-C., & Tseng, L.-M. (2017) · Oncotarget · doi:10.18632/oncotarget.23055 · Cited by 296
Ferritinophagy/ferroptosis: Iron‐related newcomers in human diseases
Tang, M., Chen, Z., Wu, D., & Chen, L. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26954 · Cited by 290
System Xc−: a key regulatory target of ferroptosis in cancer
Liu, M.-R., Zhu, W.-T., & Pei, D.-S. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01070-0 · Cited by 254
Metabolic reprogramming in triple-negative breast cancer
Wang, Z., Jiang, Q., & Dong, C. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0210 · Cited by 248
“Meanwhile, mucin 1 (MUC1), a transmembrane glycoprotein that is aberrantly overexpressed in TNBC, binds directly to the intracellular domain of CD44v and further promotes the stability of xCT 43 .”
Background
Metadata
- Authors
- Hasegawa, M., Takahashi, H., Rajabi, H., Alam, M., Suzuki, Y., Yin, L., Tagde, A., Maeda, T., Hiraki, M., Sukhatme, V. P., & Kufe, D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-22
- Volume
- 7
- Issue
- 11
- Pages
- 11756-11769
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2346455216
- Cited by
- 191
- References
- 6
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.